Zai Lab Announces Inclusion Of VYVGART And Other Medicines In China's 2023 National Reimbursement Drug List
Portfolio Pulse from Benzinga Newsdesk
Zai Lab Limited (NASDAQ: ZLAB) has announced the inclusion of its medicines VYVGART, NUZYRA, and ZEJULA in China's 2023 National Reimbursement Drug List (NRDL). VYVGART is listed for treating generalized myasthenia gravis, NUZYRA for bacterial pneumonia and skin infections, and ZEJULA for ovarian cancer maintenance treatment.
December 13, 2023 | 6:54 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Zai Lab's inclusion of VYVGART, NUZYRA, and ZEJULA in China's 2023 NRDL may lead to increased market access and potential revenue growth in the Chinese market.
The inclusion of Zai Lab's drugs in the NRDL is a significant regulatory milestone that typically leads to broader market access and insurance coverage, which can significantly increase the adoption and sales of these drugs in China. This is likely to have a positive impact on Zai Lab's short-term revenue prospects in the Chinese market.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100